DNMT3B -579G>T (rs1569686G>T) polymorphism and the risk of multiple sclerosis in a subset of Iranian population
Background: Deoxyribonucleic acid (DNA) methyltransferase 3 beta (DNMT3B) gene encodes an MT enzyme involving in de novo methylation of DNA. The present investigation aimed to explore the association of DNMT3B-579G>T (rs1569686) polymorphism with multiple sclerosis (MS).
Methods: 130 Iranian patients with MS and 130 controls were genotyped for the DNMT3B-579G>T using polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) method.
Results: There was no statistically significant association between DNMT3B-579G>T and susceptibility to MS. The alleles and genotypes of DNMT3B-579G>T did not have different risks of MS development under various models [T vs. G (P = 0.86); GTvs. GG (P = 0.48); TT vs. GG (P > 0.99); GT+TT vs. GG (P = 0.60), and TT vs. GG+GT (P = 0.87)]. Also, there was no statistically significant association between genotypes and clinical and demographic characteristics of patients (P > 0.05).
Conclusion: The current findings suggest that DNMT3B-579G>T is probably not a crucial potential risk marker in molecular diagnostics of MS among Iranian. However, to the best of our knowledge, this is the ﬁrst genetic association study about the DNMT3B polymorphisms and MS. Therefore, further surveys should be included to estimate the exact relevance of DNMT3B gene to the development of autoimmune disorders like MS.
2. Westerlind H, Ramanujam R, Uvehag D, Kuja-Halkola R, Boman M, Bottai M, et al. Modest familial risks for multiple sclerosis: A registry-based study of the population of Sweden. Brain 2014; 137(Pt 3): 770-8.
3. Handel AE, Giovannoni G, Ebers GC, Ramagopalan SV. Environmental factors and their timing in adult-onset multiple sclerosis. Nat Rev Neurol 2010; 6(3): 156-66.
4. Cotsapas C, Mitrovic M. Genome-wide association studies of multiple sclerosis. Clin Transl Immunology 2018; 7(6): e1018.
5. Chao MJ, Ramagopalan SV, Herrera BM, Lincoln MR, Dyment DA, Sadovnick AD, et al. Epigenetics in multiple sclerosis susceptibility: Difference in transgenerational risk localizes to the major histocompatibility complex. Hum Mol Genet 2009; 18(2): 261-6.
6. Castro K, Casaccia P. Epigenetic modifications in brain and immune cells of multiple sclerosis patients. Mult Scler 2018; 24(1): 69-74.
7. Jones PA. Functions of DNA methylation: Islands, start sites, gene bodies and beyond. Nat Rev Genet 2012; 13(7): 484-92.
8. Wang Z, Lu Q, Wang Z. Epigenetic alterations in cellular immunity: New insights into autoimmune diseases. Cell Physiol Biochem 2017; 41(2): 645-60.
9. Zhang P, Su Y, Lu Q. Epigenetics and psoriasis. J Eur Acad Dermatol Venereol 2012; 26(4): 399-403.
10. Jeffries MA, Sawalha AH. Autoimmune disease in the epigenetic era: How has epigenetics changed our understanding of disease and how can we expect the field to evolve? Expert Rev Clin Immunol 2015; 11(1): 45-58.
11. McDonald WI, Compston A, Edan G, Goodkin D, Hartung HP, Lublin FD, et al. Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel on the diagnosis of multiple sclerosis. Ann Neurol 2001; 50(1): 121-7.
12. Yazdanpanahi N, Etemadifar M, Kardi MT, Shams E, Shahbazi S. Investigation of ERG gene expression in iranian patients with multiple sclerosis. Immunol Invest 2018; 47(4): 351-9.
13. Farrokhi M, Masoudifar A, Derakhshan A, Saadatmand S, Rouhi-Boroujeni H, Etemadifar M, et al. The association of interleukin-16 gene polymorphisms with il-16 serum levels and risk of multiple sclerosis. Immunol Invest 2017; 2017: 1-9. [Epub ahead of print].
14. Farrokhi M, Moeini P, Fazilati M, Nazem H, Faraji S, Saadatpour Z, et al. Polymorphisms in CD14 gene may modify soluble CD14 Levels and represent risk factors for multiple sclerosis. Immunol Invest 2016; 2016: 1-8. [Epub ahead of print].
15. Andlauer TF, Buck D, Antony G, Bayas A, Bechmann L, Berthele A, et al. Novel multiple sclerosis susceptibility loci implicated in epigenetic regulation. Sci Adv 2016; 2(6): e1501678.
16. Yanagisawa Y, Ito E, Yuasa Y, Maruyama K. The human DNA methyltransferases DNMT3A and DNMT3B have two types of promoters with different CpG contents. Biochim Biophys Acta 2002; 1577(3): 457-65.
17. Zhu S, Zhang H, Tang Y, Liu P, Wang J. DNMT3B polymorphisms and cancer risk: a meta analysis of 24 case-control studies. Mol Biol Rep 2012; 39(4): 4429-37.
18. Khorshied MM, El-Ghamrawy MK. DNA methyltransferase 3B DNMT3B -579G>T) promotor polymorphism and the susceptibility to pediatric immune thrombocytopenic purpura in Egypt. Gene 2012; 511(1): 34-7.
19. Duan F, Cui S, Song C, Dai L, Zhao X, Zhang X. Systematic evaluation of cancer risk associated with DNMT3B polymorphisms. J Cancer Res Clin Oncol 2015; 141(7): 1205-20.
20. Coppede F, Bosco P, Tannorella P, Romano C, Antonucci I, Stuppia L, et al. DNMT3B promoter polymorphisms and maternal risk of birth of a child with Down syndrome. Hum Reprod 2013; 28(2): 545-50.
21. Ahmadi K, Soleimani A, Irani S, Kiani A, Ghanadi K, Noormohamadi Z, et al. DNMT3B -579 G>T promoter polymorphism and the risk of gastric cancer in the west of Iran. J Gastrointest Cancer 2018; 49(2): 167-71.
22. Hu J, Fan H, Liu D, Zhang S, Zhang F, Xu H. DNMT3B promoter polymorphism and risk of gastric cancer. Dig Dis Sci 2010; 55(4): 1011-6.
23. Srivastava K, Srivastava A, Mittal B. DNMT3B -579 G>T promoter polymorphism and risk of gallbladder carcinoma in North Indian population. J Gastrointest Cancer 2010; 41(4): 248-53.
24. Liu H, Jiao Y, Guan Y, Lao Y, Zhao C, Fan H. The DNMT3B -579 G>T promoter polymorphism and risk of lung cancer. Exp Ther Med 2012; 3(3): 525-9.
25. Guo X, Zhang L, Wu M, Wang N, Liu Y, Er L, et al. Association of the DNMT3B polymorphism with colorectal adenomatous polyps and adenocarcinoma. Mol Biol Rep 2010; 37(1): 219-25.
26. Liu Z, Wang L, Wang LE, Sturgis EM, Wei Q. Polymorphisms of the DNMT3B gene and risk of squamous cell carcinoma of the head and neck: A case-control study. Cancer Lett 2008; 268(1): 158-65.
27. Mostowska A, Sajdak S, Pawlik P, Lianeri M, Jagodzinski PP. DNMT1, DNMT3A and DNMT3B gene variants in relation to ovarian cancer risk in the Polish population. Mol Biol Rep 2013; 40(8): 4893-9.
28. Coppede F, Ricciardi R, Denaro M, De RA, Provenzano C, Bartoccioni E, et al. Association of the DNMT3B -579G>T polymorphism with risk of thymomas in patients with myasthenia gravis. PLoS One 2013; 8(11): e80846.
29. Zhao H, Du W, Gu D, Wang D, Xue F, Ge J, et al. DNMT3B 579G>T promoter polymorphism and the risk for idiopathic thrombocytopenic purpura in a Chinese population. Acta Haematol 2009; 122(1): 31-5.
30. Cai TT, Zhang J, Wang X, Song RH, Qin Q, Muhali FS, et al. Gene-gene and gene-sex epistatic interactions of DNMT1, DNMT3A and DNMT3B in autoimmune thyroid disease. Endocr J 2016; 63(7): 643-53.
31. Zhong X, Peng Y, Yao C, Qing Y, Yang Q, Guo X, et al. Association of DNA methyltransferase polymorphisms with susceptibility to primary gouty arthritis. Biomed Rep 2016; 5(4): 467-72.
32. Chomyk AM, Volsko C, Tripathi A, Deckard SA, Trapp BD, Fox RJ, et al. DNA methylation in demyelinated multiple sclerosis hippocampus. Sci Rep 2017; 7(1): 8696.
33. Arakawa Y, Watanabe M, Inoue N, Sarumaru M, Hidaka Y, Iwatani Y. Association of polymorphisms in DNMT1, DNMT3A, DNMT3B, MTHFR and MTRR genes with global DNA methylation levels and prognosis of autoimmune thyroid disease. Clin Exp Immunol 2012; 170(2): 194-201.